Brian Chee

Managing Partner

Brian is a managing partner in the San Francisco office and focuses on investments in healthcare companies. He joined Polaris as an associate in Boston, shortly after the firm was founded in 1996. Brian works with several Polaris portfolio companies including Ajax Health, August Bioservices, Neumora Therapeutics, Nomad Health, and Quartet Health, and serves as chair of Lola Development and US HealthVest.

Brian is a decorated veteran, having served as Captain in the US Army Corps of Engineers. His service included the command of combat engineer soldiers during the Gulf War. As platoon leader, Brian was awarded the Bronze Star and the Army Commendation Medal with Valor for successfully completing missions while encountering enemy fire on the front lines. Brian currently serves as a mentor with ACP helping veterans find their next career.

On behalf of Polaris, Brian has been a director of Ascend Health (Universal Health Services), Asthmatx (Boston Scientific), BridgePoint Medical (Boston Scientific), Data Sciences International (Harvard Bioscience), Free & Clear (Alere Health/United Health Group), PartsSource (Great Hill Partners), Respicardia (Zoll Medical), and Sentillion (Microsoft).

Prior to Polaris, Brian gained experience in the New York and San Francisco offices of Goldman Sachs and at Baxter Healthcare, a global, diversified healthcare company, with expertise in medical devices, pharmaceuticals, and biotechnology.

Brian received his BS from the United States Military Academy at West Point and his MBA from the Tuck School of Business at Dartmouth College.

This website is not an advertisement. This website is intended solely to provide general business information on Polaris Partners and any affiliates thereof (collectively, “Polaris”). Nothing on this website should be construed as an offer of investment advisory services by Polaris or a solicitation or an offer of interests in any Polaris fund. Visitors to this website are not to construe the contents of this website or any prior or subsequent communication from Polaris or any of its representatives, as legal, tax or investment advice. References to specific companies are for illustrative purposes only and do not represent all of the companies recommended for advisory clients. Such references are not intended to be, and should not be interpreted as, recommendations or investment advice. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed, and Polaris disclaims any duty to update any of the information and data contained herein. Certain statements may be deemed forward-looking, but any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. Where applicable, figures include investments made directly and indirectly by the Polaris Main Funds and may include co-investments with the Polaris Growth Funds and the Polaris Innovation Funds. Please see the complete list of investments here, as well as the Terms of Use for additional information and disclosures.


The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.